James Thrall Biography and Net Worth

Director of Lantheus

Dr. James H. Thrall is a Director and a member of the Nominating and Corporate Governance Committee and the Chair of the Science and Technology Committee, serving on the Board of Directors since February 2018. Dr. Thrall currently holds the Juan M. Taveras Professorship of Radiology at Harvard Medical School, having also served as Chairman of the Department of Radiology at the Massachusetts General Hospital from 1988 until 2013. Previously, Dr. Thrall served as Chairman of Radiology at the Henry Ford Hospital between 1983 and 1988, where he also served as a Physician Trustee and held the position of Vice Chairman of the Board of Governors of the Henry Ford Medical Staff. Dr. Thrall is a member of the National Academy of Medicine and has served in leadership and board of directors positions at many U.S. and international medical and professional societies. Dr. Thrall received his M.D. from the University of Michigan in 1968 and trained in Radiology and Nuclear Medicine at the Walter Reed Army Medical Center, Washington, D.C. Dr. Thrall returned to the University of Michigan in 1975 and was promoted to Professor in 1981.

What is James H. Thrall's net worth?: The estimated net worth of James H. Thrall is at least $3.31 million as of January 15th, 2025. Dr. Thrall owns 33,207 shares of Lantheus stock worth more than $3,313,062 as of March 25th. This net worth estimate does not reflect any other assets that Dr. Thrall may own. Learn More about James H. Thrall's net worth.
How do I contact James H. Thrall?: The corporate mailing address for Dr. Thrall and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at ir@lantheus.com. Learn More on James H. Thrall's contact information.
Has James H. Thrall been buying or selling shares of Lantheus?: During the past quarter, James H. Thrall has sold $94,760.00 of Lantheus stock. Most recently, James H. Thrall sold 1,000 shares of the business's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a transaction totalling $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares of the company's stock, valued at $3,146,695.32. Learn More on James H. Thrall's trading history.
Who are Lantheus' active insiders?: Lantheus' insider roster includes Minnie Baylor-Henry (Director), Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Brian Markison (CEO & Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Gary Pruden (Director), Andrea Sabens (CAO), James Thrall (Director), and Carol Walker (SVP). Learn More on Lantheus' active insiders.
Are insiders buying or selling shares of Lantheus?: During the last year, insiders at the medical equipment provider sold shares 15 times. They sold a total of 137,231 shares worth more than $12,590,187.37. The most recent insider tranaction occured on March, 17th when CFO Robert J Jr. Marshall sold 10,000 shares worth more than $1,005,200.00. Insiders at Lantheus own 1.5% of the company. Learn More about insider trades at Lantheus.
Information on this page was last updated on 3/17/2025.

James H. Thrall Insider Trading History at Lantheus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/15/2025	Sell	1,000	$94.76	$94,760.00	33,207

James H. Thrall Buying and Selling Activity at Lantheus

Lantheus Company Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Today's Range

Now: $99.77

$97.32

$100.45

50 Day Range

MA: $92.91

$78.23

$110.01

2 Week Range

Now: $99.77

$57.92

$126.89

Volume

529,526 shs

Average Volume

935,433 shs

Market Capitalization

$6.83 billion

P/E Ratio

16.60

Dividend Yield

N/A

Beta

0.38